02157 LEPU BIO-B
- 4.560
- -0.360-7.32%
LEPU BIO-B News
Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7%
Lepu Biopharma (HKG:2157) will present three clinical studies during a meeting of the American Society of Clinical Oncology, according to a Friday filing with the Hong Kong Stock Exchange. The biophar
Changes in Hong Kong stocks | Lepu Bio-B (02157) fell more than 12% from the monthly high point and already fell 35% to raise HK$230 million in the proposed discounted placement of shares
Lepu Bio-B (02157) fell more than 12% in the intraday period, to a low of HK$4.23. It is already 35% lower than the monthly high of HK$6.5. As of press release, it decreased by 7.52% to HK$4.55, with a turnover of HK$357.44,300.
Lepu Bio-B (02157.HK): Results of three clinical studies were announced at the 2024 ASCO Annual Meeting
On May 24, GLONGHUI (02157.HK) announced the results of three clinical studies of the company's innovative drug candidates and combination therapies (including antibody drug conjugates (“ADC”) MRG004A, MRG003 and HX008, and combination therapy with HX008 and Nirapali at the 2024 American Society of Clinical Oncology (“ASCO”) annual meeting.
Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5%
Lepu Biopharma (HKG:2157) will issue about 51.2 million H-shares to at least six placees for net proceeds of approximately HK$229.8 million, according to a Friday listing on the Hong Kong bourse. The
[Hong Kong Stock Connect] Lepu Biotech (02157) falls 5.5% and plans to discount 13.09% of the allotment of shares to raise HK$230 million net
Jinwu Financial News | Lepu Biotech (02157) traded shares at a discounted price and fell in response. As of press release, it reported HK$4.98, down 5.5%, with a turnover of HK$31.21,000. According to the announcement, on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, it is intended to allocate a maximum of 51.17 million H shares to no less than six independent undertakers, accounting for approximately 3.09% and 2.99% of the expanded H shares and the total issued share capital, respectively. The placement price per share was HK$4.58, a 13.09% discount on the closing price of HK$5.27 on the previous trading day. Allocate
Lepu Bio-B (02157.HK) plans to place up to 51.17 million shares to raise a total of HK$234 million
Gelonghui, May 17, 丨 Lepu Bio-B (02157.HK) announced that on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, the placement agent conditionally agreed to act as the company's agent to place up to 51.17 million shares at the placement price of HK$4.58 per H share. Placed shares accounted for about 3.19% and 3.08% of the company's total issued H shares and all existing issued share capital as at the date of this announcement; they also each accounted for the company's financial allocations
Lepu Biopharma Co., Ltd.'s (HKG:2157) 58% Share Price Surge Not Quite Adding Up
Lepu Biopharma Co., Ltd. (HKG:2157) shareholders have had their patience rewarded with a 58% share price jump in the last month. But the gains over the last month weren't enough to make shareholder
樂普生物-B：2023年度報告
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 7% to complete clinical trial of a drug to treat advanced solid tumors
Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
Is Lepu Biopharma (HKG:2157) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to rui
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 5%, commercialization achieved a breakthrough, and revenue soared 1347% last year
Lepu Bio-B (02157) rose more than 5%. As of press release, it rose 5.95% to HK$3.56, with a turnover of HK$3.336,800.
Looking at the increase in value of Lepu Bio-B (2157.HK) from an annual report that “combines speed and quality”
In 2023, due to the combined effects of macroeconomic factors such as global economic fluctuations, capital market performance was not ideal. In particular, the innovative drug sector of Hong Kong stocks continued to fluctuate and adjust. The market further released pessimistic values, and sector valuations also fell to a historically low range for a while. At the same time, the domestic healthcare industry's financing environment has also been significantly affected. According to the Sino-Thai International Research Report, the total financing of the domestic healthcare industry fell 30.1% year on year to 10.9 billion US dollars in 2023, equivalent to about 1/3 of 2021 and falling back to around 2017. Pan Tianqi of the League of Nations Foundation believes that the present is just what is expected
Breakthrough in business development and commercialization, Lepu Bio-B (02157)'s revenue in 2023 soared 1347% to 225 million yuan
Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 2.25 during the reporting period...
LEPU BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Lepu Bio-B (02157.HK) held a board meeting on March 27 to consider and approve annual results
Glonghui March 15 | Lepu Bio-B (02157.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and deal with other matters.
LEPU BIO-B: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 13% at the end of the session, and a candidate drug candidate for pancreatic cancer was granted fast track status by the US
Lepu Bio-B (02157) rose more than 13% at the end of the session. As of press release, it was up 9.09% to HK$3.6, with a turnover of HK$10.4921 million.
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation
The US Food and Drug Administration granted Lepu Biopharma (HKG:2157) fast-track status for its MRG004A pancreatic cancer treatment, according to a Monday filing with the Hong Kong bourse. The designa
Lepu Bio-B (02157): MRG004A for the treatment of pancreatic cancer was granted fast-track status by the FDA
Lepu Bio-B (02157) announced that the company's drug candidate MRG004A (a novel targeted tissue factor...
Analysis
Price Target
No Data
